Pfizer’s PAXLOVID™ receives FDA approval for adult patients at high risk of progression to severe COVID-19 Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) approved PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment…
DUPIXENT® (DUPILUMAB) LATE-BREAKING PHASE 3 COPD RESULTS PRESENTED AT ATS AND SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive Phase 3 results evaluating the investigational use of Dupixent® (dupilumab) compared to…
Lilly’s Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation Eli Lilly and Company (NYSE: LLY) has allocated an additional $50 million to its now $300 million Social Impact Venture Capital Portfolio, reflecting the company’s commitment to going beyond…
Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center Boehringer Ingelheim breaks ground to build a new Chemical Innovation Plant at its headquarters in Ingelheim, Germany. In the presence of German Chancellor…
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Supplemental New Drug Applications (sNDAs) for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for patients…
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health GSK plc (LSE/NYSE: GSK) and BELLUS Health Inc. (TSX/NASDAQ: BLU) today announced that they have entered into an agreement under which GSK will acquire BELLUS, a Canada-based, late-stage biopharmaceutical company…
Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) In Certain Patients With Advanced Melanoma (LEAP-003) and Metastatic Colorectal Cancer (LEAP-017) RAHWAY, N.J. & NUTLEY, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside of…
Merck Ranked No. 1 in the Pharmaceutical Industry Among Barron’s 100 Most Sustainable U.S. Companies 2023 RAHWAY, N.J.‐‐(3BL MEDIA)‐‐Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has been named one of Barron’s 100 Most Sustainable…
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Padcev® (enfortumab vedotin-ejfv) for First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the…
Update to contractual arrangements between AstraZeneca, Swedish Orphan Biovitrum AB and Sanofi AstraZeneca, Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the development and commercialisation of nirsevimab in the US. Given…
Johnson & Johnson Subsidiary LTL Management LLC (“LTL”) Re-Files for Voluntary Chapter 11 to Equitably Resolve All Current and Future Talc Claims Johnson & Johnson (NYSE:JNJ) (the Company) today announced that its subsidiary LTL Management LLC (LTL) has re-filed for…
Bayer to invest a total of 60 million euros in its Ukrainian seed production site Company was part of delegation led by German Vice-Chancellor Robert Habeck to Kyiv this week / Bayer underscores commitment to Ukraine and to help rebuild…